Targeting the CREB pathway for memory enhancers
Tully T, Bourtchouladze R, Scott R, Tallman J.
Helicon Therapeutics, Inc.,
One Bioscience Park Drive,
Farmingdale, New York 11743, USA.
Nat Rev Drug Discov. 2003 Apr;2(4):267-77
ABSTRACTToday, the clinical notion of 'memory disorder' is largely synonymous with 'Alzheimer's disease.' Only 50% of all dementias are of the Alzheimer's type though, and dementias represent only the more severe of all learning/memory disorders that derive from heredity, disease, injury or age. Perhaps as many as 30 million Americans suffer some type of clinically recognized memory disorder. To date, therapeutic drugs of only one class have been approved for the treatment of Alzheimer's disease. Fortunately, basic research during the past 25 years has begun to define a 'chemistry of brain plasticity,' which is suggesting new gene targets for the discovery of memory enhancers.CREB
New brain cells
CREBs and memory
The memory switch?
Growing new brain cells
The genetics of memory
Photographic memory in flies
CREB and long-term memory
Memory promoters and suppressors
Refsand further reading
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family